These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22449788)

  • 21. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
    Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
    Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
    Butt AQ; Mills KH
    Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cells and cancer immunotherapy.
    Radford KJ; Tullett KM; Lahoud MH
    Curr Opin Immunol; 2014 Apr; 27():26-32. PubMed ID: 24513968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
    Moschella F; Proietti E; Capone I; Belardelli F
    Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
    López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
    Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.
    Durrant LG; Pudney V; Spendlove I; Metheringham RL
    Expert Opin Biol Ther; 2010 May; 10(5):735-48. PubMed ID: 20384522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy.
    Dredge K; Marriott JB; Todryk SM; Dalgleish AG
    Cancer Immunol Immunother; 2002 Nov; 51(10):521-31. PubMed ID: 12384803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.
    Schijns V; Tartour E; Michalek J; Stathopoulos A; Dobrovolskienė NT; Strioga MM
    Cytotherapy; 2014 Apr; 16(4):427-39. PubMed ID: 24280238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy of cancer: targeting cancer during active disease or during dormancy?
    Shah SA; Zarei M; Manjili SH; Guruli G; Wang XY; Manjili MH
    Immunotherapy; 2017 Sep; 9(11):943-949. PubMed ID: 29338608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases.
    Švajger U; Jeras M
    Int Rev Immunol; 2012 Jun; 31(3):202-22. PubMed ID: 22587021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppressive networks in the tumour environment and their therapeutic relevance.
    Zou W
    Nat Rev Cancer; 2005 Apr; 5(4):263-74. PubMed ID: 15776005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
    Whiteside TL
    Expert Opin Biol Ther; 2010 Jul; 10(7):1019-35. PubMed ID: 20415597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
    Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
    Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumour immunotherapy: the adjuvant treatment of the 21st century?
    Bremers AJ; Kuppen PJ; Parmiani G
    Eur J Surg Oncol; 2000 Jun; 26(4):418-24. PubMed ID: 10873365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy.
    Bhutia SK; Mallick SK; Maiti TK
    Cell Biol Int; 2010 Apr; 34(5):553-63. PubMed ID: 20384587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.